Skip to main content

Repare Therapeutics Inc(RPTX-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low2.62
Day High2.65
Open:2.64
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Repare Therapeutics Inc

Select a category then submit the form to load news
Tipranks
Repare Therapeutics completes acquisition and goes private
Tipranks
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics
Business Wire
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Tipranks
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million
Tipranks
Repare Therapeutics Sells RP-3467 Program to Gilead
Tipranks
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout
Tipranks
Repare Therapeutics announces CSO resignation and transition plan
Business Wire
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Tipranks
Repare Therapeutics Announces Acquisition by XenoTherapeutics
Tipranks
TD Cowen downgrades Repare Therapeutics (RPTX) to a Hold
Tipranks
Repare Therapeutics to be Acquired by XenoTherapeutics in Strategic Move
Business Wire
RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders
Business Wire
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
Tipranks
Repare Therapeutics Unveils Phase 1 LIONS Trial Data
Business Wire
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Tipranks
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves
Tipranks
Repare Therapeutics (RPTX) Receives a Buy from TD Cowen
Tipranks
Repare Therapeutics Announces Licensing Deal and Strategic Updates
Motley Fool
Repare (RPTX) Q2 Loss Narrows 52%
Business Wire
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Tipranks
Repare Therapeutics Signs Licensing Deal with Debiopharm
Tipranks
LifeSci Capital Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
Business Wire
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
Tipranks
Repare Therapeutics (RPTX) Gets a Buy from TD Cowen
Tipranks
LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)
Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Tipranks
LifeSci Capital Keeps Their Hold Rating on Repare Therapeutics (RPTX)
Business Wire
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Business Wire
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Tipranks
Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide
Tipranks
LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)
Tipranks
Cathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop

Profile

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.